
Psychedelic substances like 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) show therapeutic potential, but their mechanisms of action through the 5-HT1A receptor are not well understood. This study provides structural, pharmacological, and behavioral insights that can guide the development of 5-HT1A-targeted psychedelic therapeutics for neuropsychiatric disorders.


coremsg

Detailed analyses of the serotonin receptor 5-HT1A and the psychedelic 5-methoxy-N,N-dimethyltryptamine reveal the differences in receptor structural pharmacology that mediate signalling specificity, efficacy and potency, findings that may facilitate the development of new neuropsychiatric therapeutics.

Structural pharmacology and therapeutic potential of 5-methoxytryptamines - Nature

structural-pharmacology-and-therapeutic-potential-of-5-methoxytryptamines-insights-into-5-ht1a-receptor-signaling-and-psychedelic-drug-development


Structural Pharmacology and Therapeutic Potential of 5-Methoxytryptamines: Insights into 5-HT1A Receptor Signaling and Psychedelic Drug Development
